Oncolytic adenovirus products:
H101(Oncorine)
H102
H103(AD-HE)

Projects in development:
　Sunway Biotech Co. Ltd wants to develop its products. The principal strategy for the clinical development programs will be based on market needs and Sunway Biotech’s core clinical competency in NSCLC and HNSCC (see Clinical Trial). In the interim, the company will continue to develop its expertise in colon cancer, breast cancer, and hepatocellular carcinoma based on large market needs. The company will also conduct most of its exploratory clinical programs in China and use its well-developed protocols to guide the design of overseas studies. Sunway Biotech Co. Ltd will focus in its future efforts in developing H101, H102, H103 in China and Onyx-015 in US and Europe.

Research:
　Sunway Biotech Co. Ltd has always known how to succeed in working with the best Chinese researchers and medical infrastructures. Sunway Biotech’s is based on a strong research capacity and meticulous clinical trials that have always entirely respected the patients’ will, safety and privacy.

Intellectual property:
　Sunway Biotech Co. Ltd has implemented a very aggressive patent strategy to establish a leading position in the development and manufacture of bioengineered, adenovirus-based targeted oncolytic immune therapies for the treatment of human cancers. Sunway Biotech’s portfolio includes 11 international patent applications with already six granted and 10 patent applications in China with 1 granted. To which Sunway Biotech Co. Ltd can add the Onyx-015 patents from Onyx pharmaceuticals. Hence one can see that Sunway Biotech Co. Ltd is in a very strong position for the manufacture and use of bioengineered adenoviruses for the treatment of multiple types of cancer.

Publications
1. Wang Yu, Hu Fang. Clinical Trails with Oncolytic Adenovirus in China. Curreent Cancer Drug Targets. 2007; 7: 659-670.

2. x-w Ren, M Liang, X Meng, X Ye, H Ma, Y Zhao,J Guo, N Cai, H-Z Chen, S-L Ye and F Hu. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for therapy of hepatocellular carcinoma. Cancer Gene Therapy 2006;13, 159-168.

3. Xia Z-J, Chang J-H, Zhang L, Jiang W-Q, Guan Z-Z, Liu J-W, Zhang Y, Hu X-H, Wu G-H, Wang H-Q, Chen Z-C, Chen J-C, Zhou Q-H, Lu J-W, Fan Q-X, Huang J-J, Zheng X. Phase III Randomized Clinical Trial of Intratumoral Injection of E1B Gene- deleted Adenovirus (H101) Combined with Cisplatin-based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus. Ai Zheng. 2004;23(12): 1593-1597.

4. Xu R-H, Yuan Z-Y, Guan Z-Z, Cao Y, Wang H-Q, Hu X-H, Feng J-F, Zhang Y, Li F, Chen Z-T, Wang J-J, Huang J-J, Zhou Q-H, Song S-T. Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer. Ai Zheng. 2003;22(12):1307-1310.

5. Yuan Z-Y, Zhang L, Li S, Qian X-Z, Guan Z-Z. Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer. Ai Zheng. 2003;22(3):310-313.

6. Ma J, Qiang P-L, Liang M, Zhang Y, Yang C-M, Ye Y-H, Pu R-L, Han L.The biological distribution of an genetically engineered adenovirus H101. Zhong Guo Yao Li Tong Xun. 2003;20(1):46-47.

7. Huang X-F, Ren W-H, Rollins L, Pittman P, Shah M, Shen L, Gu Q-L, Strube L, Hu F, and Chen S-Y. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 2003;63:7321-7329.

8. Ye X, Liang M, Meng X, Ren X-W, Chen HZ, Li Z-Y, Ni SH, Lieber A, Hu F. Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors. Biochem Biophy Res Commu. 2003;307(4):759-64.

9. Liang M, Ye X, Hu F, et al. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J virol. 2002;76:10994-11002.